Abstract

Michael Stark

Despite impressive progress in various medical fields, the suggested post-operative Oncological Chemotherapy is still based on statistical results. The FDA approved dozens of therapeutic monoclonal antibodies for metastatic colorectal cancer, which means that none is the optimal one. Some improvement has been shown when the potential of genetic profiling of tumors enabled targeted chemotherapy. In order to further improve the outcome, the New European Surgical Academy (NESA) initiated the VIEZION project for optimal post-operative oncological treatment which involves next to targeted chemotherapy the Pre Implantation Factor (PIF), stem cell therapy and immunology. PIF, with its 15-amino acid structure, is unique for all mammals and prevents rejection of the conceptus by its host. It was found to be useful in many fields such as prevention of brain injury due to ischemia, protecting against irradiation and functions like a steroid without being one, avoiding its side effects. We believe that the PIF will have a major future role in oncological treatment. Recently the role of Intalipid is being studied, and it has been shown that anesthetic medication based on fatty acids might prevent spread of cancer cells during surgery. To improve the post-operative oncological outcome the NESA created an international oncological advisory board with members from different countries, comprising basic science members, geneticists, stem-cell scientists, and oncologists. Physicians and patients from different countries are already approaching the board and occasionally original and non-conventional modes of treatments are been suggested.